Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 6/20 | 1.00 |
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 1.00 |
| ▸ | GRIN2D known ✓ | O15399 | 5/20 | 1.00 |
| ▸ | GRIN3B known ✓ | O60391 | 5/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 5/20 | 1.00 |
| ▸ | GRIN2C known ✓ | Q14957 | 5/20 | 1.00 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 0.93 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL20409394 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL15672299 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL21309814 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL4098 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL15532073 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL21310017 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL23859927 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL8996708 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL17559292 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Amantadine SCHEMBL5569374 | 0.96 | GRIN1 (0.93) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130302863-A1 | COMPOSITIONS CONTAINING HIGH OMEGA-3 AND LOW SATURATED FATTY ACID LEVELS | FERMENTALG (FR) | 2013-11-14 | — | — | US | disclosed |
| CN-101531637-B | A novel compound capable of restraining and blocking M2 ion channel activity and application thereof | CHINESE ACADEMY OF SCIENCES GUANGZHOU INST OF BIOMEDICINE AND HEALTH | 2011-07-13 | — | — | CN | disclosed |
| EP-2180884-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | The Regents of the University of Colorado, a body corporate (US) | 2010-05-05 | — | — | EP | disclosed |
| CN-101531637-A | A novel compound capable of restraining and blocking M2 ion channel activity and application thereof | CHINESE ACADEMY OF SCIENCES GU | 2009-09-16 | — | — | CN | disclosed |
| WO-2009014762-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1981478-A2 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | Regents of the University of Colorado (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1833313-A2 | COMPOSITIONS CONTAINING HIGH OMEGA-3 AND LOW SATURATED FATTY ACID LEVELS | Photonz Corporation Limited (NZ) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007084541-A2 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2004024151-A1 | COMPOSITION AND POTENTIATING METHOD | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| EP-1311286-A4 | TREATMENT OF HEPATITIS C WITH THYMOSIN AND PEGYLATED INTERFERON | SCICLONE PHARMACEUTICALS INC (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1311279-A1 | TREATMENT OF HEPATITIS C WITH THYMOSIN, INTERFERON AND RIBAVIRIN | Sciclone Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1311286-A1 | TREATMENT OF HEPATITIS C WITH THYMOSIN AND PEGYLATED INTERFERON | Sciclone Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1274461-A2 | RHAMM PEPTIDE CONJUGATES | Cangene Corporation (CA) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002011754-A1 | TREATMENT OF HEPATITIS C WITH THYMOSIN AND PEGYLATED INTERFERON | SCICLONE PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002011749-A1 | TREATMENT OF HEPATITIS C WITH THYMOSIN, INTERFERON AND RIBAVIRIN | SCICLONE PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001080899-A2 | RHAMM PEPTIDE CONJUGATES | CANGENE CORPORATION (CA) | 2001-11-01 | — | — | WO | disclosed |
| US-6162459-A | Acyclovir transdermal delivery system | NATIONAL SCIENCE COUNCIL (TW) | 2000-12-19 | — | — | US | disclosed |
| US-5074891-A | Using aromatic fluorine-containing polyimide | HOECHST CELANESE CORP. (US) | 1991-12-24 | — | — | US | disclosed |